KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Announces Publication of Sebetralstat Phase 2 Data in The Lancet

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors today

Related Keywords

Frankfurt ,Brandenburg ,Germany ,Jarrod Aldom ,Andrew Crockett ,Andrea Zanichelli ,Emel Ayg ,Exchange Commission ,Kalvista Pharmaceuticals Inc ,Corporate Communications ,University Hospital Frankfurt ,Nasdaq ,Kalvista Pharmaceuticals ,Principal Investigator ,San Donato ,Chief Executive Officer ,About Kalvista Pharmaceuticals ,Vista Pharmaceuticals ,Securities Litigation Reform Act ,Marcel Torney ,Kalvista ,Pharmaceuticals ,Nnounces ,Publication ,Sebetralstat ,Hase ,Data ,Lancet ,